Hypersympathicotonia as a link in the cardiorenal continuum: the place of moxonidine in modern antihypertensive therapy | Ukrainian Medical Journal

Hypersympathicotonia is an important pathophysiological link in hypertension and the cardiorenal continuum, as it contributes not only to an increase in blood pressure, but also to the development of metabolic disorders, albuminuria, and target organ damage. The article examines the role of increased sympathetic activity in the formation of cardiometabolic and renal risk, as well as the place of moxonidine as a centrally acting antihypertensive drug. Data on its effect on blood pressure, sympathetic tone, albuminuria, and individual metabolic parameters are summarized. Moxonidine has been shown to be useful in phenotypically selected patients with hypertension, obesity, metabolic syndrome, tachycardia, albuminuria, or chronic kidney disease.

References

1. Esler M., Kaye D. (2000) Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J. Cardiovascular Pharmacol., 35(7 Suppl. 4): S1–S7. doi.org/10.1097/00005344-200000004-00001.
2. Grassi G., Pisano A., Bolignano D. et al. (2018) Sympathetic nerve traffic activation in essential hypertension and its correlates: Systematic reviews and meta-analyses. Hypertension, 72(2): 483–491. doi.org/10.1161/HYPERTENSIONAHA.118.11038.
3. Ernsberger P. (2000) Pharmacology of moxonidine: An I1-imidazoline receptor agonist. J. Cardiovascular Pharmacol., 35(7 Suppl. 4): S27–S41. doi.org/10.1097/00005344-200000004-00005.
4. Bousquet P., Hudson A., García-Sevilla J.A. et al. (2020) Imidazoline receptor system: The past, the present, and the future. Pharmacological Reviews, 72(1): 50–79. doi.org/10.1124/pr.118.016311.
5. Prichard B.N.C. (1994) Clinical experience with moxonidine. Cardiovascular Drugs and Therapy, 8(Suppl. 1): 49–58. doi.org/10.1007/BF00877084.
6. Wenzel R.R., Spieker L., Qui S. et al. (1998) I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertension. Hypertension, 32(6): 1022–1027. doi.org/10.1161/01.HYP.32.6.1022.
7. Wenzel R.R., Mitchell A., Siffert W. et al. (2004) The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress. Br. J. Clin. Pharmacol., 57(5): 545–551. doi.org/10.1111/j.1365-2125.2003.02058.x.
8. Hausberg M., Tokmak F., Pavenstädt H. et al. (2010) Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J. Hypertens., 28(9): 1920–1927. doi.org/10.1097/HJH.0b013e32833c2100.
9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4 Suppl.): S117–S314. doi.org/10.1016/j.kint.2023.10.018.
10. Krespi P.G., Makris T.K., Hatzizacharias A.N. et al. (1998) Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovascular Drugs and Therapy, 12(5): 463–467. doi.org/10.1023/A:1007702132210.
11. Strojek K., Grzeszczak W., Górska J. et al. (2001) Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: Novel approach to prevent progression of diabetic nephropathy? J. Am. Society Nephrol., 12(3): 602–605. doi.org/10.1681/ASN.V123602.
12. Chazova I., Schlaich M.P. (2013) Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: Principal results of the MERSY study. Int. J. Hypertens., 2013, Article 541689. doi.org/10.1155/2013/541689.
13. Haenni A., Lithell H. (1999) Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J. Hypertens., 17(Suppl. 3): S29–S35.
14. Valensi P., Jambart S. (2024) MARRIAGE: A randomized trial of moxonidine versus ramipril or in combination with ramipril in overweight patients with hypertension and impaired fasting glucose or diabetes mellitus. Impact on blood pressure, heart rate and metabolic parameters. J. Cardiovascular Pharmacol. Therapeut., Advance online publication. doi.org/10.1177/10742484241258381.
15. Sanjuliani A.F., de Abreu V.G., Braga J.U. et al. (2004) Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J. Clin. Basic Cardiol., 7(1–4): 19–25. http://www.kup.at/journals/summary/4932.html.
16. Pöyhönen-Alho M.K., Manhem K., Katzman P. et al. (2008) Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. J. Hypertens., 26(12): 2445–2449. doi.org/10.1097/HJH.0b013e328311cf37.
17. Shorakae S., Lambert E.A., Jona E. et al. (2018) Effect of central sympathoinhibition with moxonidine on sympathetic nervous activity in polycystic ovary syndrome — A randomized controlled trial. Front. Physiol., 9: Article 1486. doi.org/10.3389/fphys.2018.01486.
18. Schlaich M.P., Tsioufis K., Taddei S. et al. (2024) Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: An international position statement. J. Hypertens., 42(12): 2025–2040. doi.org/10.1097/HJH.0000000000003769.
19. Вьорваг Фарма ГмбХ і Ко. КГ. (n.d.). Моксогама^® (моксонідин), таблетки, вкриті плівковою оболонкою, 0,4 мг. Інструкція для медичного застосування. mozdocs.kiev.ua/likiview.php?id=19759.